Let's take a closer look at each of these medications. Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient ...

Semaglutide is now approved for T2D patients with CKD, reducing cardiovascular and kidney disease risks. The FLOW phase 3b trial showed significant reductions in adverse kidney and cardiovascular ...

Female sex, antidepressant use, and type of health insurance significantly influence semaglutide initiation. (HealthDay News) — Sociodemographic, health care, and clinical factors are associated with ...

Kidney disease treatment is undergoing a transformation, driven by exciting new research that reveals the protective power of semaglutide in patients with type 2 diabetes. Semaglutide, a ...

The weight loss drug semaglutide was a "miracle" for Staci Rice. Her cravings and "food noise" disappeared, and it help her lose 64 pounds in around eight months. But, even in its cheaper forms ...

Treatment with once-weekly semaglutide 7.2 mg conferred a 20.7% weight reduction vs. a 17.5% weight loss with semaglutide 2.4 mg. The safety profile of semaglutide 7.2 mg is similar to other GLP-1s.

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...